Compass Therapeutics, Inc.: Form 10-Q for the period ended Sep 30, 2020
Filed with the SEC on Nov 9, 2020 and accepted by EDGAR at Nov 9, 2020, 12:31 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2020-09-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Research and development | 3 months2020-07-01 to 2020-09-30 | $3.7m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months2020-01-01 to 2020-09-30 | $10.5m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2020-07-01 to 2020-09-30 | −$9.0m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2020-01-01 to 2020-09-30 | −$19.9m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2020-07-01 to 2020-09-30 | $212.0k | us-gaap:InterestExpense |
| Interest expense | 9 months2020-01-01 to 2020-09-30 | $730.0k | us-gaap:InterestExpense |
| Income tax | 9 months2020-01-01 to 2020-09-30 | $32.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2020-07-01 to 2020-09-30 | −$9.2m | us-gaap:NetIncomeLoss |
| Net income | 9 months2020-01-01 to 2020-09-30 | −$21.1m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2020-07-01 to 2020-09-30 | −$0.18 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted EPS | 9 months2020-01-01 to 2020-09-30 | −$0.88 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 9 months2020-01-01 to 2020-09-30 | −$20.2m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months2020-01-01 to 2020-09-30 | $23.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2020-09-30 | $55.5m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2020-09-30 | $57.8m | us-gaap:AssetsCurrent |
| Total assets | At period end2020-09-30 | $60.7m | us-gaap:Assets |
| Current liabilities | At period end2020-09-30 | $9.7m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2020-09-30 | $13.4m | us-gaap:Liabilities |
| Long-term debt | At period end2020-09-30 | $3.7m | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | At period end2020-09-30 | $7.5m | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | At period end2020-09-30 | $47.3m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001564590-20-052190. Last ingested by Listed: Oct 24, 2026, 15:07 ET. Listed shows no prices and gives no investment advice.